SEC Comment Letter for AEON Biopharma, (AEON) — Feb 12, 2026
AEON Biopharma, Inc.
Date: Feb. 12, 2026 · CIK: 0001837607 · Accession: 0000000000-26-001525
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293309
Letter
Re: AEON Biopharma, Inc. Registration Statement on From S-3 Filed February 09, 2026 File No. 333-293309 Dear Robert Bancroft:
February 12, 2026
Robert Bancroft President and Chief Executive Officer AEON Biopharma, Inc. 5 Park Plaza Suite 1750 Irvine, CA 92614
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Drew Capurro, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> February 12, 2026 Robert Bancroft President and Chief Executive Officer AEON Biopharma, Inc. 5 Park Plaza Suite 1750 Irvine, CA 92614 Re: AEON Biopharma, Inc. Registration Statement on From S-3 Filed February 09, 2026 File No. 333-293309 Dear Robert Bancroft: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Drew Capurro, Esq. </TEXT> </DOCUMENT>